Filing Flows

Filing Flows › Aquestive Therapeutics (AQST) › Next earnings date

Aquestive Therapeutics (AQST) earnings: beat the estimate

Aquestive Therapeutics (AQST) reported on Nov 3, 2026 and beat the EPS estimate: −$0.11 against −$0.14 (+16.1%). Revenue was $7.6M for Q3 2026, -41% year over year. It beat the EPS estimate in 60% of the quarters on record.

Last result+16.1% vs estimate
Beat rate60%

The last report

Aquestive Therapeutics reported revenue of $7.6M for the third quarter 2026 (-41% Y/Y), net loss $16.5M: Manufacture and supply revenue $6.7M, License and Royalty Revenue $824K, Co-development and research fees $74K. How it makes money → · Every quarter →

Aquestive Therapeutics: EPS against the estimate, last 5 reportsAquestive Therapeutics: EPS against the estimate, last 5 reportsEstimateReported−$0.11−$0.11Nov 25−$0.12−$0.14Mar 26−$0.13−$0.05May 26−$0.12−$0.07Aug 26−$0.14−$0.11Nov 26
Latest (Nov 26): Estimate −$0.14, Reported −$0.11.

Aquestive Therapeutics' latest quarter

Aquestive Therapeutics, Q3 2026: revenue $7.6M (-41% year over year), operating margin -191.5%, net loss $16.5M, operating cash flow −$7.0M. The chart follows the revenue to costs, profit and cash.

Questions

Did Aquestive Therapeutics beat earnings?

Aquestive Therapeutics (AQST) reported on Nov 3, 2026 and beat the EPS estimate: −$0.11 against −$0.14 (+16.1%).

When does AQST report earnings?

The next date is not set yet.

Does Aquestive Therapeutics usually beat earnings?

It beat the consensus EPS estimate in 60% of the quarters on record.

Open the interactive view →

Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.